Takeda Pharmaceutical Return On Equity vs. Return On Asset

TKPHF Stock  USD 25.26  0.29  1.14%   
Taking into consideration Takeda Pharmaceutical's profitability measurements, Takeda Pharmaceutical Co may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Takeda Pharmaceutical's ability to earn profits and add value for shareholders.
For Takeda Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Takeda Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Takeda Pharmaceutical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Takeda Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Takeda Pharmaceutical Co over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Takeda Pharmaceutical Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Takeda Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Takeda Pharmaceutical value to that of its competitors to determine the firm's financial worth.
Takeda Pharmaceutical Co is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about  0.52  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Takeda Pharmaceutical Co is roughly  1.93 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Takeda Pharmaceutical's earnings, one of the primary drivers of an investment's value.

Takeda Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Takeda Pharmaceutical

Return On Equity

 = 

Net Income

Total Equity

 = 
0.0477
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Takeda Pharmaceutical

Return On Asset

 = 

Net Income

Total Assets

 = 
0.0247
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Takeda Return On Asset Comparison

Takeda Pharmaceutical is currently under evaluation in return on asset category among its peers.

Takeda Pharmaceutical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Takeda Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Takeda Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Takeda Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Takeda Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutica operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 47347 people.

Takeda Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Takeda Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Takeda Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Takeda Pharmaceutical's important profitability drivers and their relationship over time.

Use Takeda Pharmaceutical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Takeda Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Takeda Pharmaceutical Pair Trading

Takeda Pharmaceutical Co Pair Trading Analysis

The ability to find closely correlated positions to Takeda Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Takeda Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Takeda Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Takeda Pharmaceutical Co to buy it.
The correlation of Takeda Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Takeda Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Takeda Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Takeda Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Takeda Pharmaceutical position

In addition to having Takeda Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate ETFs Thematic Idea Now

Real Estate ETFs
Real Estate ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 66 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Takeda Pink Sheet

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out World Market Map.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
To fully project Takeda Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Takeda Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Takeda Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.
Potential Takeda Pharmaceutical investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Takeda Pharmaceutical investors may work on each financial statement separately, they are all related. The changes in Takeda Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Takeda Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.